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Impact of 9-Valent Human Papillomavirus Vaccine on HPV Vaccination Coverage of Youths, Ages 
9-17, in North Carolina
SECONDARY OBJECTIVE
Design: Individual-level retrospective cohort
Outcome: Indicator variable for receiving 9vHPV (relative to other HPV 
vaccine type)
Key explanatory variables: Youth and area-level demographic 
characteristics and other area-level market characteristics
Analysis
• Logistic regression
• Separate regressions by sex
PRIMARY OBJECTIVE
Design: Area-level interrupted time series
Outcomes: Area-level uptake (doses), initiation, completion, and 
compliance rates
Key explanatory variable: Indicator for the introduction of 9vHPVin NC in 
July 2015
Analysis
• De-trended monthly time series to remove time trend and seasonality
• Regression on an indicator variable for ZCTA/months post release of 
9vHPV
North Carolina Immunization Registry (NCIR)
• January 2008 through October 2016
• Youth between the ages of 9 and 17 years in 2016
• Complete vaccination history for this cohort of youth
• Excluded youth in the NCIR with missing values for date of 
the HPV vaccine, HPV vaccine type, sex or ZIP code
• Primary objective: aggregated data to ZIP Code 
Tabulation Areas (ZCTAs)
• Secondary objective: restricted sample to doses of HPV 
vaccine administered during or after July 2015 
(introduction of 9vHPV in NC)
Human Papillomavirus (HPV) Vaccination
• Most common sexually-transmitted infection in the United 
States
• Causes genital warts, and is associated with cervical, 
vaginal, vulvar, anal, penile, and throat cancers 
• Routine vaccination at age 11 or 12 years has been 
recommended by the Advisory Committee on 
Immunization Practices (ACIP) since 2006 for females and 
since 2011 for males
HPV Vaccination Rates
• In 2015, completion of the three-dose series among 
adolescents ages 13 to 17 was:
• 42% for girls
• 28% for boys
• HPV vaccination coverage also lags far behind childhood 
and other adolescent vaccines.
HPV Vaccine Types
• Quadrivalent HPV vaccine (4vHPV) and 9-valent HPV 
vaccine (9vHPV) are currently licensed and indicated for 
use among both females and males in the US to protect 
against several of the most common HPV types 
associated with cancer. 
• Bivalent HPV vaccine (2vHPV) is indicated for females 
only
• 9vHPV is the most recent HPV vaccine to enter the market
• Food and Drug Administration approval in 
December 2014
• ACIP recommendation in February 2015
Objectives:
• The primary objective was to evaluate the impact of 
introduction of 9vHPV vaccine on 
• HPV vaccination uptake (# doses)
• Initiation (>1 dose)
• Completion  (>3 doses)
• Compliance (>3 doses within 1 year)
• The secondary objective was to describe timing of 
administration and characteristics of children who received 
9vHPV compared to those who received another HPV 
vaccine (2vHPV or 4vHPV) beginning in July 2015.
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• Introduction of 9vHPV was not associated with changes in 
HPV vaccination rates in NC as measured by doses per 
capita or initiation, completion or compliance rates
• Results did not change when we also included ZCTA-level 
characteristics and allowed for autoregression in the error 
terms.
Secondary objective
• Following the introduction of 9vHPV, youth receiving the 
HPV vaccine were more likely to receive 9vHPV than 
other HPV vaccine types if they lived in a ZCTA with
• a larger age-eligible (i.e., 9 to 17) population, 
• a health professional shortage area, or 
• a higher number of annual outpatient visits per 
capita.
• Following the introduction of 9vHPV, youth receiving the 
HPV vaccine were less likely to receive 9vHPV than other 
HPV vaccine types if
• they were older, 
• received a publicly-funded dose, or 
• lived in a ZCTA with a higher percentage of the 
population with less than a high-school education or
• a higher number of religious organizations. 
Limitations
• NCIR does not include complete coverage of privately 
funded vaccines, vaccines given by pharmacies or to 
youths who may have moved out of state
• Not representative of U.S. or areas of country with 
different demographics and regional patterns of care
• Bias could remain from changes in unobserved 
confounders concurrent with the introduction of 9vHPV 
(e.g., changes in outreach policies in the state)
Summary
• Introduction of 9vHPV was not associated with changes in 
HPV vaccination rates in NC
• Transition from 4vHPVto 9vHPV was quick
• Disparities in the diffusion of 9vHPV across areas of NC
Figure 1. Population-weighted ZCTA-level HPV vaccination doses per capita by month
9vHPV 
Introduced
Table 1.  Individual-level logistic regression model for receiving 9vHPV vaccine type after July 2015
Bold indicates significance at the 95% confidence level. 
Quarter fixed effects and intercept not shown. Standard errors clustered by ZCTA.
 Female Male 
 N=146,405 doses N=145,893 doses 
 Odds ratio 95% CI Odds ratio 95% CI 
Age 0.98 (0.97, 0.99) 0.97 (0.96, 0.98) 
White race 1.00 – 1.00 – 
African American race 1.00 (0.94, 1.05) 0.98 (0.93, 1.03) 
Other race 1.19 (1.06, 1.33) 1.13 (1.02, 1.25) 
Publicly funded dose 0.59 (0.54, 0.64) 0.58 (0.54, 0.63) 
Age-eligible ZCTA population (in units of 10,000) 2.10 (1.62, 2.73) 2.03 (1.54, 2.67) 
Percent of ZCTA population that is female 0.52 (0.02, 15.0) 1.46 (0.06, 33.56) 
Percent of ZCTA population that is non-White 1.05 (0.69, 1.60) 0.94 (0.62, 1.42) 
Percent of ZCTA population with less than high school education 0.20 (0.04, 0.82) 0.12 (0.03, 0.54) 
Percent of ZCTA population with a college degree 0.73 (0.32, 1.66) 0.55 (0.25, 1.25) 
Percent of ZCTA population in persistent poverty 0.89 (0.66, 1.20) 0.79 (0.63, 1.00) 
Indicator for health professional shortage area 1.19 (1.02, 1.38) 1.17 (1.01, 1.36) 
Number of annual outpatient visits per capita in ZCTA 1.05 (1.02, 1.08) 1.05 (1.01, 1.08) 
Number of religious organizations per capita in ZCTA 0.86 (0.77, 0.98) 0.85 (0.76, 0.94) 
 
